Bevacizumab, a recombinant monoclonal antibody targeting VEGF‐A, is one of the most widely available anti‐VEGF therapies and has demonstrated a synergistic effect with EGFR‐TKIs against EGFR mutation‐positive lung cancers.8, 9. This evidence concerns the gene EGFR and lung carcinoma.